January 28, 2021
January 28, 2021 | New products for high-content imaging, virus reagents and enrichment, software for small molecule design, and pharmacokinetic simulation. Plus: acquisitions in drug discovery services and partnerships for data analysis, single cell analysis, machine learning, and more.
Certara has released
version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform. Simcyp PBPK Simulator version 20 offers new and enhanced models for maternal health, such as assessing drug performance during pregnancy and lactation. It also automates the assessment of virtual bioequivalence to attain biowaivers and analyzes drugs delivered via long-acting injectable delivery. Additional upgrades have been made to the Simcyp PBPK Simulator’s animal, liver, absorption, and skin models. Press release.
January 27th, 2021
BSIP via Getty Images
Artificial intelligence and machine learning systems continue to be adopted into an ever wider array of healthcare applications, such as assisting doctors with medical image diagnostics. Capable of understanding X-rays and rapidly generating MRIs sometimes even able to spot cases of COVID these systems have also proven effective at noticing early signs of breast cancer which might otherwise be missed by radiologists. Google and IBM, as well as medical centers and university research teams around the world, have all sought to develop such cancer-catching algorithms.
MIT
They can spot worrisome lumps as well as radiologists can and predict future onsets of the disease “significantly” better than the humans that trained them. However many medical AI imaging systems produce markedly less accurate results for black and brown people despite WOC being 43 percent more likely to die from breast cancer compared to their white counterparts